Atlas Trials

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Clinical trial NCT01211262 · COMPLETED

Trial details

NCT number
NCT01211262
Sponsor
Immunocore Ltd
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Malignant Melanoma
Start date
2010-09-28
Primary completion
2016-02-16
Enrollment
84

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.